303-771-9000Are you in need of treatment for your chronic inflammatory demyelinating polyneuropathy (CIPD)?
Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
The Study
- Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, chronic autoimmune disease of the peripheral nervous system characterized by progressive weakness and impaired sensation
- The disease can be disabling, though the degree of disability varies; more than half of patients cannot walk unaided when symptoms are at their worst
- Both cellular and humoral components of the immune system have been implicated and evidence suggests that a number of autoantibodies identified in CIDP patients are pathogenic
Study Benefits:
- Compensation for time and travel
- Free medication and study related care
- May benefit your CIDP symptoms
Study Participant Criteria :
- 18 years of age or older
- Diagnosed with active CIDP
- Male or female
Study Participant Expectations :
- 11-week treatment period
- 8 visits to the research clinic and 6 interim phone calls
“Did You Know”
- Epidemiological studies estimate that the prevalence of CIDP ranges from 0.67-10.3 cases per 100,000 people
- CIDP predominantly affects males, and typically occurs in middle to old age; the incidence increases with age, rising to 1.5 times the overall average in people over 65 years of age